Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab phase 2 study in adults with chronic spontaneous urticaria resistant to H1-antihistamines
2017-004458-41Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in chronic idiopathic urticaria (CIU), chronic urticaria (CU), sponsored by Charité – Universitätsmedizin Berlin. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)chronic urticaria (CU)
Beyond the preview
Go deeper on 2017-004458-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004458-41.